Neurological disorders Archives

News and Trends 11 Feb 2016

Sanofi-Genzyme: Still successful 5 years after the acquisition?

Back in 2011, France’s biggest Pharmaceutical company Sanofi decided to purchase Genzyme Corp. for more than $20 billion, thus becoming the latest global drug giant to acquire a big biotech to foster its R&D pipeline. 5 years later, what’s the situation for Genzyme and Sanofi? So often when a large Pharma acquires a smaller Biotech, […]

February 11, 2016 - 3 minutesmins - By Dani Bancroft

3d bioprinting brain neurology harvard inserm cnrs finland

News and Trends 4 Feb 2016

Finland, France and Harvard Bioprint Brains to Understand the 3D Structure

Researchers at Harvard University in collaboration with French and Finnish academic institutions have managed to 3D-bioprint a brain with the distinctive folds; An essential adaptation for our cognitive development. Harvard University worked with the CNRS at Aix Marseille Université (France), Institut Mines-Telecom INSERM (France) and the University of Jyväskylä (Finland). The team then published in Nature Physics what they discovered […]

February 4, 2016 - 3 minutesmins - By Dani Bancroft

alzheimers dementia discovery fund takeda weizmann biogen rodin

News and Trends 25 Jan 2016

Also Using PD-L1 Cancer Treatments to Attack Alzheimer’s Disease

What updates have occurred in the Neurodegenerative disease field as of late? New appointments by the Dementia Discovery Fund, which widens its international reach – and new ‘out of the box’ ideas from Israel and South Korea. The Dementia Discovery Fund (DDF), an innovative global investment fund managed by SV Life Sciences and launched in October […]

January 25, 2016 - 3 minutesmins - By Dani Bancroft

polyganics microaire groningen medtech biotech neurosurgery

News and Trends 22 Jan 2016

Groningen’s MedTech Hub for Neurosurgery is Actually a Biotech Hotspot

I visited Groningen (Netherlands) and the University Medical centre there in November, and it was interesting to note the tight knit Biotechnology and medical research bubble which has been enlarging, now making multiple outbound research and clinical trial links to the US. One such example is Polyganics, which has signed an exclusive distribution agreement with its US strategic […]

January 22, 2016 - 3 minutesmins - By Dani Bancroft

biogen alzheimer proteros rodin therapeutics atlas neurology

News and Trends 8 Jan 2016

Epigenetics Baby of Proteros is Signing Up with Top US Neurology Specialists

Founded in just 2013 by German Proteros and the US Atlas Ventures, Rodin Therapeutics is working epigenetics into discovery of novel therapies for Neurological diseases. Now they have hooked one of the largest players in the field, Biogen, into a €446M partnership. Since its inception within Atlas Venture’s company-creating seed program in March 2013, Rodin […]

January 8, 2016 - 3 minutesmins - By Dani Bancroft

brains imba cerebral organoids neurological disease

News and Trends 6 Jan 2016

Growing Mini-Brains in Labs to Better Understand Neurological Disease

Mini brains, about 3-4 mm are a breakthrough in Neurology which will enable researchers to study the development of neurological disease and perform drug tests ex vivo. Scientists from Institute of Molecular Biotechnology (IMBA) in Vienna are underpinning the secrets behind the most fascinating human’s organ, the brain. By essentially growing brains from scratch, the […]

January 6, 2016 - 2 minutesmins - By Joachim Eeckhout

News and Trends 22 Dec 2015

Dutch Organ-on-Chip Biotech Hauls in €1.5M Funding from Pharma Syndicate in Project Against Animal Testing

Mimetas from Leiden (NL) has now been financed to develop an Organ-on-Chip (tissue model) to specifically test Neurotoxicity, as a piece of medtech to help clinical trials move away from Animal testing… Organs-on-Chips are microfluidic tissue models which mimic basic organ-to-organ coupling. Developed with the aim of simulating ADMET testing and drug screening in vitro, […]

December 22, 2015 - 3 minutesmins - By Dani Bancroft

probiodrug small molecule alzheimers disease trial

News and Trends 15 Dec 2015

Latest Small Molecule against Alzheimer’s Disease Success in Phase I Trials

Probiodrug‘s phase I tolerability and efficacy trial for Alzheimer’s didn’t quite go as planned, although results are in and it is still good news for this small molecule candidate. Probiodrug in Halle (Germany) is pioneering immunotherapy approaches to eliminate pyroglutamated (pGlu) Abeta, a highly toxic peptide that has been linked to the progression of Alzheimer’s […]

December 15, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 7 Dec 2015

Hydra’s Immortality is not Myth: Polyps Genetically Reprogram Skin Cells into Neurons

Relatives of the Jellyfish, researchers at the University of Geneva (Switzerland) have now proven the regenerative abilities of Hydra involved reprogramming cells. Does this have any implications for Neurodegenerative disease? Remember the Greek myth of Hydra? Amongst other twelve labours, Hercules had to slay the nine-headed monster Hydra which, in case nine jaws weren’t enough, […]

December 7, 2015 - 3 minutesmins - By Lourdes Riquelme

cytotools medday stock black friday drop phase III fail

News and Trends 4 Dec 2015

Black Friday Ruin as TWO Biotechs Fail in Phase III Trials

A shocking Black Friday for these two Biotechs: Both CytoTools (Germany) and MedDay (France) phase III trials in chronic disease flopped massively, and stocks dropped as much as 85% in one day… Multiple Sclerosis Headliner, MedDay’s MD1003, has flopped in its phase III trial after failing to meet its primary endpoint. This is a disastrous […]

December 4, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 30 Nov 2015

Heptares’ G-Protein StaR Platform has now Hooked Pfizer in a Billion Euro Deal

Heptares Therapeutics from the UK has landed Pfizer in a huge potential $1.9Bn deal for their G-protein receptor platform. Heptares Therapeutics was founded by Fiona Marshall (one of our Top 10 UK Women in Biotech), who now serves as a CSO to Japanese Big boss Sosei, which wholly acquired Heptares earlier this year in a […]

November 30, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 26 Nov 2015

The UK-Israeli €378M Small-Molecule Offensive Against Migraines

The Israeli TEVA and UK Heptares Therapeutics (now owned by Japanese Sosei) have partnered up on novel drug therapies targeting Migraines. The pain and disruption migraines can cause pain that lasts from 4 to 72 hours, and around 10 million worldwide suffer such episodes on a regular basis. Signs and symptoms of a migraine include photosensitivity […]

November 26, 2015 - 2 minutesmins - By Dani Bancroft

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us